| Inventor | Institute |
|---|---|
| Bill Gullick | University College London (UCL), UK |
| SKU: | 151158 |
|---|---|
| Product description: | Anti-ErbB3 [RTJ2] is a monoclonal antibody which binds ErbB3. ErbB3 (c-erbB-3/HER-3) is a type I growth factor receptor and binds to ligands in the heregulin family. ErbB3 is over-expressed in a variety of tumours in the bladder, breast, colon, pancreas and stomach. By immunoprecipitation, this antibody detects a protein representing HER-3 from human tissue extracts. This antibody has also been used in immunohistochemistry, immunofluorescence, western blotting and ELISA procedures using human tissues. |
| Alternate name: | Anti-ErbB3 antibody |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Synthetic peptide of human ErbB3 |
| Immunogen Uniprot ID: | P21860 |
| Myeloma used: | NS0 |
| Cat. #: | 151158 |
|---|---|
| Provenance and Ownership: | The Anti-ErbB3 [RTJ2] mAb is owned by Cancer Research UK. CancerTools supplies the Anti-ErbB3 [RTJ2] mAb under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-ErbB3 [RTJ2] mAb directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer; Cell biology; Cell signaling and signal transduction |
| Application: | ELISA ; FACS ; IHC ; IF ; IP ; WB |
| Target: | ErbB3 (Her3) |
| Reactivity: | Human |
| Clone: | RTJ2 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Benterud et al. 1976. Tidsskr Nor Laegeforen. 96(31):1647-1648. PMID: 982398. |
| Target background: | The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB3 is normally found in non-dividing differentiated epithelial cells, neurones and hepatocytes. It has approximately 80% prevalence in a wide variety of tumours of the gastro-intestinal tract, and approximately 20% prevalence in breast cancer. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Almadori et al. 2010. Eur J Cancer. 46(6):1144-1152. PMID: 20149638. Anagnostou et al. 2010. Cancer Epidemiol Biomarkers Prev. 19(4):982-991. PMID: 20332259. Okwueze et al. 2007. J Invest Dermatol. 127(5):1030-1041. PMID: 17124505. Srinivasan et al. 1998. J Pathol. 185(3):236-245. PMID: 9771476. Rajkumar et al. 1995. Int J Oncol. 6(1):105-109. PMID: 21556509. Benterud et al. 1976. Tidsskr Nor Laegeforen. 96(31):1647-1648. PMID: 982398. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.